Windward Bio Group (NASDAQ:WWB) Director Orbimed Advisors Llc Acquires 1,176,471 Shares of Stock

Windward Bio Group AG (NASDAQ:WWB – Get Free Report) Director Orbimed Advisors Llc acquired 1,176,471 shares of the business’s stock in a transaction on Monday, November 16th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $20,000,007.00. Following the purchase, the director directly owned 1,708,103 shares of the company’s stock, valued at $29,037,751. This represents a 221.29% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Windward Bio Group Stock Down 12.1%

NASDAQ:WWB traded down $3.12 during trading hours on Wednesday, reaching $22.64. 518,194 shares of the stock were exchanged, compared to its average volume of 334,031. Windward Bio Group AG has a 52 week low of $18.35 and a 52 week high of $33.99.

About Windward Bio Group

(Get Free Report)

Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.

Recommended Stories

Receive News & Ratings for Windward Bio Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windward Bio Group and related companies with MarketBeat.com's FREE daily email newsletter.